A MESSAGE FROM OUR FOUNDER/CEO:

New partnership brings growth evolution and new opportunities

I am excited to share big news for Suttons Creek and our clients. Following years of exponential growth, we sought partnership that could offer expertise and support for scaling the highest level of quality for managed services and consulting in the combination product space. Our team is happy to announce that we have found that partner in the ToxStrategies portfolio of companies. This pharmaceutical services partnership includes ToxStrategies, Modality Solutions and Clintrex Research, with support from Renovus Capital Partners, a private equity firm specializing in healthcare and professional services.

Our new business will run as usual, but even better!  We’re now operating as a separate division of a company that has additional teams to support you. There are no changes planned for how we support clients or for which team members will support our client programs. You are still able to use our same contact information. Rob Schulz and I will continue to lead Suttons Creek as a separate division of ToxStrategies. Our industry-leading combination product expertise will remain the same, but Suttons Creek can now offer a broader portfolio of services in the areas of toxicology, epidemiology, clinical trials, and therapeutic product development. This expanded set of capabilities continues our goal of providing integrated teams and turnkey solutions across the pharmaceutical development and commercialization lifecycle. For more information on our acquisition, read ToxStrategies’ announcement published today.

We look forward to the growth evolution this alliance will provide and will continue to keep you informed of offerings and opportunities it brings to the pharmaceutical industry. To stay in the “know,” follow our LinkedIn page and subscribe to our emails.

Sincerely,

Steve Badelt, Phd